# Strategic Transformation of the Market of HCV Treatments

> **NCT02961426** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Drugs for Neglected Diseases** · enrollment: 603 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** sofosbuvir + ravidasvir

## Key facts

- **NCT ID:** NCT02961426
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2021-08
- **Final completion:** 2024-03
- **Target enrollment:** 603 (ACTUAL)
- **Last updated:** 2021-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961426, "Strategic Transformation of the Market of HCV Treatments". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02961426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*